Comparing Contineum Therapeutics (NASDAQ:CTNM) & Orchestra BioMed (NASDAQ:OBIO)

Contineum Therapeutics (NASDAQ:CTNM) and Orchestra BioMed (NASDAQ:OBIO) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, profitability, risk, analyst recommendations, institutional ownership, dividends and earnings.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Contineum Therapeutics and Orchestra BioMed, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Contineum Therapeutics	1	1	4	0	2.50
Orchestra BioMed	1	1	5	0	2.57

Contineum Therapeutics presently has a consensus target price of $20.00, indicating a potential upside of 44.30%. Orchestra BioMed has a consensus target price of $13.60, indicating a potential upside of 234.98%. Given Orchestra BioMed’s stronger consensus rating and higher probable upside, analysts plainly believe Orchestra BioMed is more favorable than Contineum Therapeutics.

Volatility and Risk

Contineum Therapeutics has a beta of 0.89, indicating that its stock price is 11% less volatile than the S&P 500. Comparatively, Orchestra BioMed has a beta of 0.52, indicating that its stock price is 48% less volatile than the S&P 500.

Institutional and Insider Ownership

53.2% of Orchestra BioMed shares are owned by institutional investors. 11.3% of Contineum Therapeutics shares are owned by insiders. Comparatively, 7.5% of Orchestra BioMed shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Valuation & Earnings

This table compares Contineum Therapeutics and Orchestra BioMed”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Contineum Therapeutics	$50.00 million	10.36	-$59.98 million	($1.95)	-7.11
Orchestra BioMed	$33.48 million	7.26	-$52.70 million	($0.97)	-4.19

Orchestra BioMed has lower revenue, but higher earnings than Contineum Therapeutics. Contineum Therapeutics is trading at a lower price-to-earnings ratio than Orchestra BioMed, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Contineum Therapeutics and Orchestra BioMed’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Contineum Therapeutics	N/A	-27.09%	-25.64%
Orchestra BioMed	-166.96%	-157.46%	-60.18%

About Contineum Therapeutics

Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. The company was incorporated in 2009 and is headquartered in San Diego, California.

About Orchestra BioMed

Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company’s flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension (HTN); and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold devices and minimally invasive surgery devices. The company has a collaboration agreement with Medtronic, Inc. for the development and commercialization of BackBeat CNT for the treatment of HTN in patients indicated for a cardiac pacemaker; and a strategic collaboration with Terumo Medical Corporation for the development and commercialization of Virtue SAB for the treatment of coronary and peripheral artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.